Theralase Technologies Inc. TLTFF

Primary Symbol: V.TLT

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 2025 Outlook

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Nov 20, 2024 8:58pm

106 Views

Post# 36322939

RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook

CancerSlayer wrote:
BlueFranky wrote: Damn it Cancer Slayer, you never cease to provide this board with unbiased clarity and dare I say, hope.

Thanks once again for all of your efforts!

Certainly....if we were to put a lens on just clinical development stage/progress, being a company with a nearly completed Ph II (& no requirements for a Ph III) & assuming we obtain a BTD, such progress should leapfrog us into "approvable" drug territory in the eyes of Big Pharma & hence make us a prime target, especially considering all of the gaps yet to be filled due to:

1) Overly stringent selection criteria

2) Overly invasive/burdensome treatment protocols, testing &
monitoring

3) Overly costly, especially when combining two expensive therapies

4) Increased toxicity/side effects (especially for certain patient populations)
& the associated costs for treating severe side effects

5) Suboptimal efficacy & durability

6) Achieving efficacy, but lacking adequate durability

7) Achieving efficacy & durability, but at the expense of one or a combination
of the first three

Etc, etc...

We are getting close. Good luck...